Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside

Zhile Wang, Mengyao Wang, Bo Dong, Yuqing Wang, Zheyu Ding and Shensi Shen ()
Additional contact information
Zhile Wang: Sichuan University
Mengyao Wang: Sichuan University
Bo Dong: Southern Medical University
Yuqing Wang: Sichuan University
Zheyu Ding: Sichuan University
Shensi Shen: Sichuan University

Nature Communications, 2025, vol. 16, issue 1, 1-12

Abstract: Abstract Drug-tolerant persister (DTP) cells represent a major obstacle to achieving durable cancer remission, yet their biology and clinical relevance remain poorly understood. This perspective highlights key gaps hindering the translation of DTP research into clinical progress, emphasizing the need to move beyond reductionist models toward integrative, patient-aligned approaches that reflect clinical complexity. Bridging these divides will be crucial to reveal actionable biomarkers and develop therapies capable of eradicating these resilient cell populations.

Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-66376-6 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-66376-6

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-66376-6

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().